secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001193125-24-150435
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA to receive $8.1M from Viracta after Day One sells PRV for $108M
--------------------------------------------------------------------

- Day One Biopharmaceuticals sold a priority review voucher for $108M after FDA approval of OJEMDA.
- XOMA is entitled to $8.1M from Viracta under a March 2021 agreement covering tovorafenib milestones.
- The PRV sale proceeds trigger event-based economics payable to XOMA.
- Funds represent a portion of the PRV proceeds passed through from Day One to Viracta.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312524150435/0001193125-24-150435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312524150435/d839143d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-150435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer